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Abstract 
Background Little is known about prescribing appropriateness for community-dwelling people with 
dementia (PWD). 
Objective To estimate potentially inappropriate prescribing (PIP) prevalence among PWD in primary 
care in Northern Ireland, and to investigate associations between PIP and polypharmacy, age and 
gender. 
Methods A retrospective cross-sectional study was conducted, using data from the Enhanced 
Prescribing Database. Patients were eligible if a medicine indicated for dementia management was 
dispensed to them during 01/01/2013 – 31/12/2013. Polypharmacy was indicated by use of ≥4 
repeat medications from different drug groups. A subset of the Screening Tool of Older Persons 
Potentially Inappropriate Prescriptions (STOPP) criteria, comprising 36 indicators, was applied to the 
dataset. Overall prevalence of PIP and the prevalence per each STOPP criterion was calculated as a 
proportion of all eligible persons in the dataset. Logistic regression was used to investigate 
associations between PIP, polypharmacy, age and gender. 
Results The study population comprised 6826 patients. Polypharmacy was observed in 81.5% 
(n=5564) of patients. PIP prevalence during the study period was 64.4% (95% CI 63.2 – 65.5; 
n=4393). The most common instance of PIP was the use of anticholinergic/antimuscarinic 
medications (n=1718; 25.2%; 95% CI 24.2 – 26.2). In multivariable analyses, both polypharmacy and 
gender (being female) were associated with PIP, with odds ratios of 7.6 (95% CI 6.6 – 8.7) and 1.3 
(95% CI 1.2 – 1.4) respectively. No association was observed between PIP and age, after adjustments 
for gender and polypharmacy. 
Conclusion This study identified a high prevalence of PIP in community-dwelling PWD.  Future 
interventions may need to focus on certain therapeutic categories and polypharmacy. 
 
Keywords: Dementia; pharmacoepidemiology; inappropriate prescribing; polypharmacy; primary 
health care 
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INTRODUCTION 
Demographic ageing is a process taking place worldwide, and is reflective of the major 
advancements in healthcare over the last century. Consequently, prescribing for older people, 
conventionally defined as those aged 65 years and over, is becoming an increasingly important 
aspect of clinical care, and one that requires prudent consideration from prescribers [1]. The 
presence, and subsequent management of, multiple morbidities in older patients will often result in 
polypharmacy [2], which has frequently been described as the concurrent use of four or more 
medications [3, 4]. Use of ten or more medications has been termed ‘excessive polypharmacy’ [5]. 
While polypharmacy may be appropriate and therapeutically beneficial where a number of 
medications are clinically indicated (such as patients with complex or multiple conditions) [2], it is 
known to be a risk factor for adverse drug events (ADEs), drug-drug and drug-disease interactions, 
and potentially inappropriate prescribing (PIP) [3, 4, 6]. PIP refers to the use of medicines that 
introduce a greater risk of adverse drug-related events where a safer, as effective alternative is 
available to treat the same condition [6]. PIP is associated with increases in negative outcomes such 
as morbidity, ADEs, hospitalisations and mortality [7, 8], and is reported to be common amongst 
older people [9-11]. A myriad of tools have been developed to identify inappropriate prescribing [2, 
7]. The recently updated Screening Tool of Older Person’s Prescriptions (STOPP) criteria is a 
screening tool comprising 80 clinically significant criteria for PIP in older people, primarily organised 
by physiological system, validated by a Europe-wide Delphi consensus panel [12]. These evidence-
based criteria take drug-drug and drug-disease interactions, drug doses, duration of treatment, and 
clinical effectiveness into consideration when determining the appropriateness of the prescribed 
treatments. Each criterion is accompanied by a concise, evidence-based explanation as to why the 
prescribing practice is potentially inappropriate. The STOPP criteria have been extensively validated 
for use in the United Kingdom (UK) setting [2].  
 
Consideration of the appropriateness of prescribing for people with dementia (PWD) is particularly 
important due to the unique medication needs that this vulnerable population have in comparison 
to the rest of the older population. The presence of other comorbidities and complex medication 
regimens with possible psychoactive drug use, together with deficits in cognition and 
communication and diminishing decision-making capacity, generate challenges with medication 
management, particularly adherence [13]. Such issues may also influence doctors’ prescribing 
behaviour and the quality of chronic illness management [14, 15]. For example, Wood-Mitchell et al. 
reported that psychiatrists in England felt under pressure to prescribe for PWD experiencing 
behavioural and psychological symptoms and did not always adopt an evidence-based approach to 
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prescribing activity [13]. Whilst a number of studies have reported on appropriateness of prescribing 
for PWD, these tend to focus on dementia patients living in long-term care facilities [16, 17], those at 
the end of life [18, 19], or those prescribed antipsychotic medications [20, 21]. Less attention has 
been paid to PWD living in their own homes within the primary healthcare setting. Studies that have 
specifically investigated inappropriate medication use within this dementia patient population have 
been small in size and relied on patient or caregiver reports of drug use [22-26]. 
 
An assessment of the appropriateness of prescribing for PWD, especially those managed within the 
primary healthcare setting, may help to identify a population likely to benefit from interventions to 
optimise prescribing practices. Therefore, the aim of this pharmacoepidemiological study was to 
estimate the prevalence of PIP among PWD in primary care in Northern Ireland (NI), by applying a 
subset of the STOPP criteria to a prescribing database. We also sought to explore the association 
between PIP and factors such as polypharmacy, age and gender, to more precisely characterise 
those with dementia who might be at risk of PIP. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
MATERIALS AND METHODS 
Setting 
Northern Ireland is part of the UK, has a population of ~1.7 million, and primary healthcare is 
delivered through ~330 general practices. Healthcare in NI is provided under the UK’s National 
Health Service (NHS), where health and social care is publicly funded through central taxation and is 
free-of-charge at the point of need to all citizens. Unlike some other countries in the UK (namely 
England and Scotland), prescriptions (and therefore all medications) have been free in NI since 
prescription charges were phased out in 2010. 
 
Data source 
Data were extracted from the Enhanced Prescribing Database (EPD), which securely holds 
information on drugs prescribed and subsequently dispensed to patients in primary care in NI. The 
EPD does not contain data relating to prescribing in the hospital setting or over-the-counter (OTC) 
medication use. Once prescriptions have been dispensed by community pharmacies, they are 
forwarded to the Health and Social Care (HSC) Business Services Organisation (BSO) at the end of 
each month for reimbursement. Computer-generated prescriptions contain a unique two-
dimensional barcode which is scanned by the BSO during the reimbursement process. This barcode 
links a patient’s Health and Social Care Number with details of their prescribed medication and 
prescriber. Once this information is scanned by the BSO, it is held in a secure database, the EPD. At 
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present, approximately 85-90% of all prescriptions forwarded to the BSO result in data of research 
standard, which has helped to generate a central database of approximately 1.9 million patients in 
NI [9]. Diagnoses and other clinical information are not recorded in the EPD.    
 
Study design and population 
This was a retrospective, cross-sectional study using data from the EPD. Ethical approval was 
received from the NHS Research Ethics Committee London – City Road and Hampstead 
(14/LO/1891). Study participants were identified by a computerised search of the EPD, which was 
conducted by BSO data custodians. The study population comprised all individuals in the EPD who 
were dispensed a drug for the management of dementia (donepezil, galantamine, rivastigmine, 
memantine) during the study period 01/01/2013 – 31/12/2013. These drugs were used as proxy 
measures for diagnosis of dementia in the absence of clinical information about individuals. Patients 
in the EPD who entered a care home on or before 31/12/2013 were excluded, as were patients who 
left NI or died during the study period. In order to apply certain STOPP criteria, all patients were 
required to have at least three months of lead-in data prior to 01/01/2013, to ascertain long-term 
use of certain medications. All data were anonymised and the research team had no access to any 
patient identifiable data.  
 
The final version of the dataset that was available to the research team included a unique patient 
identifier and information on patients’ age (in years), gender, the month and year in which a 
prescription was scanned by the BSO, and data on all items prescribed (such as the drug name, 
strength, quantity, and date of issue) during the study period. 
 
Exposures  
Thirty-eight of the 80 STOPP indicators were deemed suitable by the research team for application 
to the EPD dataset in the absence of clinical or diagnostic information. Some indicators could not be 
applied due to the absence of clinical or diagnostic data and were therefore excluded. For example, 
‘aldosterone antagonists with concurrent potassium-conserving drugs without monitoring of serum 
potassium’ could not be operationalised due to the absence of data on biochemical monitoring, and 
therefore, was not included. For some criteria, prescription drugs for the treatment of certain 
disease conditions were identified in the EPD dataset and used as proxies for diagnosis, where 
possible, such as for glaucoma and gout (Supplementary table 1). This method has been used in 
other studies [8, 9]. During analysis, the following two STOPP indicators were unable to be 
operationalised due to lack of long-term prescribing data: ‘long-term use of NSAID for symptom relief 
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of osteoarthritis where paracetamol has already been tried’ and ‘long-term NSAID or colchicine for 
chronic treatment of gout where there is no contraindication to a xanthine-oxidase inhibitor’. 
Therefore, a total of 36 STOPP indicators were applied to the final dataset. 
 
Data on drug use were extracted using British National Formulary (a standard drug reference text 
used in the UK) codes [1]. Patients were categorised into those who received a STOPP criteria drug 
or drug combination. STOPP criteria which specified a particular duration, such as ‘benzodiazepines 
for ≥4 weeks’, were assessed by identifying individuals who used the drugs for durations exceeding 
these ‘appropriate’ thresholds within the study period (using the month a prescription was scanned 
by the BSO). STOPP criteria which specified a particular dosage not to be exceeded, such as ‘oral 
elemental iron doses greater than 200mg daily’, were evaluated by calculating the number of daily 
defined doses (DDDs) for each recipient using the strength and quantity of the dispensed medication 
for each prescription.  
 
The total number of prescriptions dispensed for each different drug group (according to BNF code) 
was calculated for each individual, during the one year study period. A ‘repeat medication’ was 
defined as one for which the patient received three or more prescriptions for that agent in the study 
period. Polypharmacy was examined by the use of four or more repeat medications from different 
drug groups.  
 
Outcomes  
The primary outcome was the overall prevalence of PIP in PWD in primary care in NI in 2013, 
according to a subset of the STOPP criteria. Secondary outcomes measures were: (i) the prevalence 
of PIP per individual STOPP criterion, and (ii) the association between PIP and polypharmacy, gender, 
and age group. 
 
Statistical analysis 
The overall prevalence of PIP in the study population and the prevalence per individual STOPP 
criterion in 2013 (the study period) were calculated as a proportion of all eligible persons in the 
dataset, and reported as percentage estimate and 95% confidence intervals (CI). Adjusted logistic 
regression analyses were used to calculate odds ratios (OR) and 95% CI to investigate the association 
between any (versus no) PIP and polypharmacy (categorised as 0-3 versus ≥4 repeat drug classes), 
age group (≤44, 45-64, 65-84, ≥85 years) and gender (male, female). There were no missing data for 
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the variables of interest. Analyses were performed using STATA SE v13 (StataCorp, College Station, 
TX, USA). 
 
RESULTS 
Characteristics of the study population 
For the study period, 6826 persons identified in the EPD were eligible for inclusion in the study 
(Table 1). Of these, approximately two-thirds were female (n=4393, 64.4%), with a mean age of 79.6 
[standard deviation (SD) ±8.0] years. Patients were taking a mean number of 6.8 (SD ±3.5) repeat 
medications. Over three-quarters of patients (n=5564, 81.5%) were receiving four or more repeat 
medications (the definition of polypharmacy adopted for this study), whilst the use of ten or more 
repeat medications was observed in one-fifth of patients (n=1427, 20.9%). 
 
[Insert Table 1 here] 
 
Overall prevalence of PIP in 2013 
The overall prevalence of PIP in the study period, according to the 36 STOPP indicators that were 
applied to the dataset, was 64.4% (95% CI 63.2 – 65.5) (n=4393). Over one-fifth of the population 
[n=1571, 23.0% (95% CI 22.0 – 24.0)] was prescribed one potentially inappropriate medication, 1141 
patients [16.7% (95% CI 15.8 – 17.6)] were prescribed two potentially inappropriate medications, 
and 1681 patients [24.6% (95% CI 23.6 – 25.7)] were prescribed three potentially inappropriate 
medications. 
 
Prevalence of PIP in 2013 according to individual STOPP criteria 
Table 2 describes the prevalence for each STOPP criterion. The most common instance of PIP was 
the use of anticholinergic/antimuscarinic medications (n=1718, 25.2%). The second most frequently 
prescribed potentially inappropriate medicines were proton pump inhibitors (PPIs) at full 
therapeutic dosage for >8 weeks (n=1561, 22.9%), followed by acetylcholinesterase inhibitors with 
concurrent treatment with drugs that reduce heart rate (n=1276, 18.7%), benzodiazepines for ≥4 
weeks (n=777, 11.4%), and use of regular opioids without concomitant laxative (n=715, 10.5%). 
Duplication of therapy within drug classes was most frequently observed with opioid analgesics 
(n=346, 5.1%) and benzodiazepines (n=239, 3.5%). Many other STOPP criteria had a prevalence less 
than 1.0%, such as ‘thiazide diuretic with a history of gout’ and ‘phenothiazines as first-line 
treatment, since safer and more efficacious alternatives exist’.  
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[Insert Table 2 here] 
 
Factors associated with PIP 
Univariate logistic regression confirmed that polypharmacy, age and gender were significantly 
associated with PIP (Table 3). A strong association between PIP and polypharmacy was observed. 
Those receiving four or more repeat medications were seven and a half times more likely to be 
exposed to PIP compared to those on zero to three repeat medications (adjusted OR 7.6, 95% CI 6.6 
– 8.7). PIP was more likely to occur in females than in males after adjusting for age and 
polypharmacy (adjusted OR 1.3, 95% CI 1.2 – 1.4). No association was observed between PIP and age 
after adjustments for gender and polypharmacy.  
 
[Insert Table 3 here] 
 
DISCUSSION 
Findings 
Based on the data from a comprehensive dispensing database of 6826 dementia patients in NI, we 
found that both polypharmacy and PIP were prevalent among this community-dwelling patient 
population during 2013. PIP occurred in nearly two-thirds of the population (64.4%), according to 
the subset of STOPP criteria applied. The most commonly prescribed potentially inappropriate 
medicines were anticholinergic/antimuscarinic medications, followed by PPIs at maximum 
therapeutic dosage for >8 weeks, acetylcholinesterase inhibitors with concurrent treatment with 
drugs that reduce heart rate, and benzodiazepines for ≥4 weeks. Polypharmacy and gender were 
significantly associated with PIP. Age was not associated with PIP. 
 
To our knowledge, this is one of the first studies to apply the STOPP criteria to a large prescribing 
database in order to ascertain the prevalence of PIP amongst community-dwelling dementia 
patients. Previous studies have reported a lower prevalence of potentially inappropriate medication 
use (between 15% and 47%) among community-dwelling dementia patients, as reported using either 
the Beers criteria or PRISCUS list (a tool developed for use in Germany) [22-26]. The prevalence of 
PIP in our study was nearly double that reported by Bradley et al. who investigated PIP in older 
people (aged ≥70 years) in NI using the STOPP criteria, but whose methodology did not focus 
specifically on PWD [10].  
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In addition, we found that the prevalence of polypharmacy, as defined by the use of four or more 
repeat medications, was high amongst this patient population (81.5%). Again, this is difficult to 
directly compare with previous studies which have used different numeric thresholds to define 
polypharmacy in their study populations. However, this finding is much greater than that reported 
by Montastruc et al. [26] and Lau et al. [23] who reported polypharmacy (≥5 medications) in 43% 
and 52% respectively of community-dwelling patients with dementia. A high prevalence of 
polypharmacy is unsurprising in PWD, as often this patient population will suffer from a number of 
comorbidities due to their increasing age and frailty [27]. Whilst patients in the current study 
population ranged in age from 34 to 100 years, they had a mean age of 79.6 years, and would 
therefore be expected to be receiving a number of different medications for comorbid conditions. 
There has been discussion within the literature about reducing reliance on numeric thresholds for 
polypharmacy and considering instead the appropriateness of polypharmacy, taking into account the 
fact that the use of ‘many drugs’ may be necessary for those with multimorbidities [2, 28]. 
 
This study revealed a number of instances of PIP; some of these, such as the use of PPIs at full 
therapeutic dosage for >8 weeks and benzodiazepines for ≥4 weeks, are unsurprising and are 
consistent with findings reported in other studies exploring PIP amongst older people [10, 11] and 
PWD in care homes [17]. The prescribing of anticholinergic/antimuscarinic medications in our study 
population, received by one-quarter of patients (25.2%), was a concerning finding. The use of these 
drugs in PWD is not recommended due to their association with decline in both physical and 
cognitive function [29], and yet other studies have found similarly prevalent use of anticholinergics 
in dementia patients [24, 26, 30]. A number of tools have been developed to measure the 
anticholinergic drug burden, such as the validated Anticholinergic Cognitive Burden Scale [31]. The 
availability of such tools to clinicians could prove invaluable during an in-depth medication review 
with dementia patients, and may help them to change patients to alternative drugs with a lower 
anticholinergic burden.  In some situations, non-pharmacological measures could be used as 
alternatives to prescribing anticholinergic medications, for example scheduling regular toilet breaks 
and making dietary modifications instead of using bladder antispasmodics [32].  
 
Practice implications 
In our study, the high prevalence of both polypharmacy and PIP could serve as an indicator that 
review of these patients is required to fully assess the appropriateness of the medication regimens 
used, particularly considering the strong relationship we observed between polypharmacy and PIP, 
which has been reported previously [9-11, 17, 22-23, 25-26]. This study also revealed that PIP among 
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community-dwelling dementia patients was associated with female gender, but not age. Again, 
these relationships have been reported elsewhere [9-11, 25-26] and would be of assistance to 
clinicians identifying patients at risk of PIP. These associations may be useful in generating 
hypotheses which could be explored in other datasets. Consideration of PIP, polypharmacy and 
gender could be incorporated into clinicians’ prescribing systems in order to alert them to such high-
risk patients and potentially inappropriate medication combinations [33]. Medication review is just 
one component of medicines optimisation, employing a patient-focused and person-centred 
approach which ensures that patients obtain the best possible outcomes from their medicines [34]. 
Often GPs find it difficult to incorporate robust medication review into consultations due to time 
constraints; opportunity therefore exists for other healthcare professionals such as community 
pharmacists and nurses to assist with this and examples of such interventions in a primary care 
setting have been reported in the literature [35-37]. With respect to pharmacists, the role of the GP 
practice-based pharmacist is expanding and a pilot scheme will be launched in the UK during 2016 
[38]. These pharmacists will be ideally placed to assist with medication review of patients and will 
also be able to identify patients at high risk from PIP and potentially inappropriate medications. 
 
Deprescribing is another way in which inappropriate medication use and polypharmacy may be 
managed [39], and could prove to be a useful intervention in this particular patient population. For 
example, ‘drug holidays’ (where medication is stopped for a trial period to assess effectiveness of 
treatment and/or remission of symptoms [40]) could be advocated for anticholinergic medications, 
such as those for urinary incontinence. Deprescribing is an emerging area within the scientific 
literature and it has been acknowledged that a wider evidence-base is needed to support such an 
approach [41-44]. It has been reported that deprescribing may be particularly complicated in PWD 
due to their diminishing capacity and involvement in decision-making about their medicines, and 
difficulties with communication and understanding [45]. Reeve et al. have called for further research 
into the beliefs and preferences of dementia patients and their carers in order to better understand 
how deprescribing can be of optimal benefit to this patient population [45]. 
 
Strengths and limitations 
This is one of the largest epidemiological studies to use a prescription-based database to estimate 
PIP amongst community-dwelling dementia patients. The EPD holds information on all prescriptions 
dispensed in community pharmacies in NI, and the high scan rate of prescriptions has generated a 
reliable database of great use to researchers. Although we have confidence in the generalisability of 
the results to the wider dementia patient population within NI, there are a number of 
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methodological limitations which may limit generalisability of the findings to other settings. The lack 
of clinical information within the EPD, notably diagnostic data, means there could be an 
underestimation of the prevalence of patients with dementia. We had to identify patients who had 
received one of four drugs used in the management of dementia, using these medications as a proxy 
for a dementia diagnosis. These drugs are licensed for the treatment of mild to moderate dementia 
in Alzheimer’s disease (donepezil, galantamine), moderate to severe dementia in Alzheimer’s 
disease (memantine) or mild to moderate dementia in Parkinson’s disease (rivastigmine) [1]. Whilst 
this may have excluded those with dementia of different aetiologies or those with severe cases in 
whom the medication had been stopped, we had no alternative means of identifying the patient 
population for inclusion in the study in the absence of diagnostic information. In addition, the lack of 
clinical data within the EPD only allowed us to apply a subset of the STOPP criteria and some 
diagnoses had to be determined using drug proxies, an analytical approach which has been used 
previously [9, 10, 46]. Therefore some instances of PIP identified within this study may not be 
clinically relevant, and clinicians must ensure that prescribing decisions are also based upon their 
clinical and personal knowledge of each patient. A set of explicit prescribing criteria for dementia is 
under development in Australia [47] and may be useful to researchers carrying out similar 
epidemiological studies in the future. The EPD was chosen for its relevance to the NI setting over 
other databases such as the Clinical Practice Research Datalink (CPRD), which is not representative 
of NI prescribing data [48]. Other limitations of using drug dispensing data is that patient adherence 
to medication is assumed. Use of over-the-counter (OTC) medications purchased without a 
prescription is not accounted for, which may under-estimate or over-estimate PIP prevalence and 
use of anticholinergic/antimuscarinic medications in particular, due to the anticholinergic effect of 
many OTC sleeping aids and antihistamines. 
 
Despite these limitations, polypharmacy and PIP are prevalent among community-dwelling dementia 
populations; female patients and those receiving four or more medications may be at particular risk 
from inappropriate prescribing practices. This study has added to the limited body of 
epidemiological work undertaken with the community-dwelling dementia population as its focus, 
and may assist clinicians to identify ‘at-risk’ dementia patients in need of medication review within 
the primary care setting. Further pharmacological studies should be undertaken to validate the 
findings from the present study in other settings, such as the rest of the UK or Europe. Future work 
should also focus on exploring GPs’ prescribing behaviours for these patients to further understand 
the factors influencing prescribing decisions. 
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TABLES 
Table 1. Characteristics of the study population in the Enhanced Prescribing Database (EPD) dataset 
(n=6826) 
Variables Prevalence, n 
(%) 
Mean 
(±SD) 
Range 
Gender    
     Male 2433 (35.6)   
     Female 4393 (64.4)   
Age (years)  79.6 (8.0) 34 – 100 
     ≤44 7 (0.1)   
     45-64 275 (4.0)   
     65-84 4582 (67.1)   
     ≥85 1962 (28.7)   
Number of repeat medications  6.8 (3.5) 1 – 23 
Polypharmacy (≥4 medications)    
     Never 1262 (18.5)   
     Ever 5564 (81.5)   
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Table 2. Prevalence of potentially inappropriate prescribing in 2013 among 6826 people with 
dementia in Northern Ireland by individual STOPP criteria 
Criteria description (potential risk) Number of 
patients 
% of patients  
(95% CI) 
Indication of medication  
Any drug prescribed beyond the recommended duration, 
where treatment duration is well defined 
  
    Zopiclone and zolpidem (up to 4 weeks) 573 8.4 (7.8 – 9.1) 
   NSAIDs (up to 3 months) 124 1.8 (1.6 – 2.2) 
Any duplicate drug class prescription (optimisation of 
monotherapy within a single drug class should be observed 
prior to considering a new agent) 
  
     Opioid analgesics 346 5.1 (4.6 – 5.6) 
     Benzodiazepines 239 3.5 (3.1 – 4.0) 
     Stimulant laxatives 45 0.7 (0.5 – 0.9) 
     SSRIs 33 0.5 (0.3 – 0.7) 
     Statins 34 0.5 (0.4 – 0.7) 
Cardiovascular system  
Beta-blocker in combination with verapamil or diltiazem (risk 
of heart block) 
18 0.3 (0.2 – 0.4) 
Amiodarone as first-line1 antiarrhythmic therapy in 
supraventricular tachyarrhythmias2 (higher risk of side-effects 
than beta-blockers, digoxin, verapamil or diltiazem) 
7 0.1 (0.05 – 0.2) 
Thiazide diuretic with a history of gout2 (gout can be 
precipitated by thiazide diuretic) 
20 0.3 (0.2 – 0.5) 
Phosphodiesterase type-5 inhibitors with concurrent nitrate 
therapy for angina2 (risk of cardiovascular collapse) 
2 0.03 (0.01 – 0.1) 
Antiplatelet/Anticoagulant drugs  
Long-term aspirin at doses greater than 150mg per day 
(increased risk of bleeding, no evidence for increased efficacy) 
24 0.4 (0.2 – 0.5) 
NSAID and vitamin K antagonist, direct thrombin inhibitor or 
factor Xa inhibitors in combination (risk of major 
gastrointestinal bleeding) 
9 0.1 (0.07 – 0.3) 
NSAID with concurrent antiplatelet agent(s) without PPI 117 1.7 (1.4 – 2.1) 
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prophylaxis (increased risk of peptic ulcer disease) 
Central nervous system and psychotropic drugs  
TCAs with dementia, narrow-angle glaucoma, cardiac 
conduction abnormalities, prostatism, or prior history of 
urinary retention2 (risk of worsening these conditions) 
  
     Dementia 335 4.9 (4.4 – 5.5) 
     Narrow-angle glaucoma 13 0.2 (0.1 – 0.3) 
     Cardiac conduction abnormalities 3 0.04 (0.01 – 0.1) 
     Prostatism or prior history of urinary retention 25 0.4 (0.3 – 0.5) 
Initiation of TCAs as first-line antidepressant treatment 
(higher risk of adverse drug reactions with TCAs than SSRIs or 
SNRIs) 
75 1.1 (0.09 – 1.4) 
Benzodiazepines for ≥4 weeks (no indication for longer 
treatment) 
777 11.4 (10.7 – 12.2) 
Antipsychotics (other than quetiapine or clozapine) in those 
with Parkinsonism or Lewy Body Disease2 (risk of severe 
extrapyramidal symptoms) 
51 0.8 (0.6 – 1.0) 
Anticholinergics/antimuscarinics to treat extrapyramidal side-
effects of neuroleptic medications (risk of anticholinergic 
toxicity) 
29 0.4 (0.3 – 0.6) 
Anticholinergics/antimuscarinics in patients with dementia2 
(risk of exacerbation of cognitive impairment) 
1718 25.2 (24.2 – 26.2) 
Acetylcholinesterase inhibitors with concurrent treatment 
with drugs that reduce heart rate such as beta-blockers, 
digoxin, diltiazem, verapamil (risk of cardiac conduction 
failure, syncope and injury) 
1276 18.7 (17.8 – 19.6) 
Phenothiazines as first-line treatment, since safer and more 
efficacious alternatives exist (phenothiazines are sedative, 
have significant antimuscarinic toxicity in older people, with 
the exception of prochlorperazine for 
nausea/vomiting/vertigo, chlorpromazine for relief of 
persistent hiccups and levopromazine as an antiemetic in 
palliative care) 
59 0.9 (0.7 – 1.1) 
First generation antihistamines (safer, less toxic 635 9.3 (8.6 – 10.0) 
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antihistamines now widely available) 
Gastro-intestinal system  
Prochlorperazine or metoclopramide with Parkinsonism2 (risk 
of exacerbating Parkinsonian symptoms) 
13 0.2 (0.1 – 0.3) 
PPI for uncomplicated peptic ulcer disease or erosive peptic 
ulcer oesophagitis2 at full therapeutic dosage for >8 weeks 
(dose reduction or earlier discontinuation indicated) 
1561 22.9 (21.9 – 23.9) 
Oral elemental iron doses greater than 200mg daily (no 
evidence of enhanced iron absorption above these doses) 
2 0.03 (0.01 – 0.1) 
Respiratory system  
Theophylline as monotherapy for COPD2 (safer, more effective 
alternatives; risk of adverse effects due to narrow therapeutic 
index) 
65 1.0 (0.8 – 1.2) 
Systemic corticosteroids instead of inhaled corticosteroids for 
maintenance therapy in moderate-severe COPD2 (unnecessary 
exposure to long-term side-effects of systemic corticosteroids 
and effective inhaled therapies are available) 
0 0.00 
Antimuscarinic bronchodilators with a history of narrow-angle 
glaucoma or bladder outflow obstruction2 (may exacerbate 
glaucoma or cause urinary retention) 
  
     Narrow-angle glaucoma 13 0.2 (0.1 – 0.3) 
     Bladder outflow obstruction 50 0.7 (0.6 – 1.0) 
Non-selective beta-blocker with a history of asthma2 requiring 
treatment (risk of increased bronchospasm) 
30 0.4 (0.3 – 0.6) 
Benzodiazepines with acute or chronic respiratory failure2 
(risk of exacerbation of respiratory failure) 
6 0.09 (0.04 – 0.2) 
Musculoskeletal system  
NSAID with severe hypertension or severe heart failure2 (risk 
of exacerbation of hypertension or heart failure) 
0 0.00 
COX-2 selective NSAIDs with concurrent cardiovascular 
disease2 (increased risk of myocardial infarction and stroke) 
24 0.4 (0.2 – 0.5) 
NSAID with concurrent corticosteroids without PPI prophylaxis 
(increased risk of peptic ulcer disease) 
20 0.3 (0.2 – 0.5) 
Urogenital system  
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Antimuscarinic drugs with dementia, or chronic cognitive 
impairment or narrow-angle glaucoma or chronic prostatism2 
(risk of increased confusion, acute exacerbation of glaucoma 
and urinary retention) 
  
     Dementia or chronic cognitive impairment 631 9.2 (8.6 – 10.0) 
     Narrow-angle glaucoma 35 0.5 (0.4 – 0.7) 
     Chronic prostatism 122 1.8 (1.5 – 2.1) 
Endocrine system  
Sulphonylureas with a long duration of action with type 2 
diabetes mellitus2 (risk of prolonged hypoglycaemia) 
2 0.03 (0.01 – 1.1) 
Thiazolidinediones in patients with heart failure2 (risk of 
exacerbation of heart failure) 
0 0.00 
Analgesic drugs  
Use of oral or transdermal strong opioids as first-line therapy 
for mild pain (WHO analgesic ladder not observed) 
49 0.7 (0.5 – 1.0) 
Use of regular3 (as distinct from PRN) opioids without 
concomitant laxative (risk of severe constipation) 
715 10.5 (9.8 – 11.2) 
Long-acting opioids without short-acting opioids for 
breakthrough pain (risk of persistence of severe pain) 
610 8.9 (8.3 – 9.6) 
Antimuscarinic/Anticholinergic drug burden  
Concomitant use of two or more drugs with 
antimuscarinic/anticholinergic properties (risk of increased 
antimuscarinic/anticholinergic activity) 
215 3.2 (2.8 – 3.6) 
STOPP, Screening Tool of Older Persons Potentially Inappropriate Prescriptions; NSAID, non-steroidal anti-inflammatory 
drug; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; PPI, proton pump inhibitor; COPD, chronic 
obstructive pulmonary disease; COX-2, cyclooxygenase-2; WHO, world health organisation; PRN, when required 
1‘First-line’ therapy was determined by examining prescribing in the three months prior to starting the drug in question 
2The use of drugs commonly indicated in certain disease conditions (such as gout, parkinsonism, glaucoma) were identified 
in the Enhanced prescribing Database (EPD) and used as proxies for diagnosis 
3An opioid was defined as being used ‘regularly’ if a patient had received a prescription for an opioid for three consecutive 
months 
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Table 3. Logistic regression analyses investigating any PIP criteria 
PIP Unadjusted OR (95% CI) Adjusted OR (95% CI) 
Polypharmacy   
     Never (ref) 1.0 1.0 
     Ever 7.5 (6.5 – 8.6) 7.6 (6.6 – 8.7) 
Gender   
     Male (ref) 1.0 1.0 
     Female 1.2 (1.1 – 1.4) 1.3 (1.2 – 1.4) 
Age group (years)   
     ≤44 (ref) 1.0 1.0 
     45-64 0.6 (0.1 – 3.2) 0.8 (0.1 – 4.6) 
     65-84 0.7 (0.1 – 3.7) 0.7 (0.1 – 4.2) 
     ≥85 0.8 (0.1 – 3.9) 0.7 (0.1 – 4.0) 
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Supplementary table 1. List of drugs used as proxies for conditions listed in STOPP criteria 
Condition Assumption(s) made Drugs used as proxies listed by British 
National Formulary (BNF) categories 
[1] from which they were extracted 
Supraventricular 
tachyarrhythmias 
Presence of supraventricular 
tachyarrhythmias was 
assumed by dispensing of 
drug indicated for SVT 
2.1.1 Cardiac glycosides 
2.4 Beta-adrenoceptor blocking 
drugs 
2.6.2 Calcium-channel blockers 
Gout Presence of gout was 
assumed by dispensing of 
drug indicated for gout 
10.1.4 Gout and cytotoxic-induced 
hyperuricaemia 
 
Angina Criterion states ‘concurrent 
nitrate therapy for angina’ 
2.6.1 Nitrates 
Dementia Presence of dementia was 
assumed by dispensing of 
drug indicated for dementia 
4.11 Drugs for dementia 
Glaucoma Presence of glaucoma was 
assumed by dispensing of 
drug indicated for glaucoma 
11.6 Treatment of glaucoma 
Cardiac conduction 
abnormalities 
Presence of cardiac 
conduction abnormalities was 
assumed by dispensing of 
anti-arrhythmic agent 
2.3.2 Drugs for arrhythmias 
Prostatism or prior 
history of urinary 
retention or bladder 
outflow obstruction 
Presence of prostatism and 
prior history of urinary 
retention was assumed by 
dispensing of drugs indicated 
for BPH or for urinary 
retention 
6.4.2 Male sex hormones and 
antagonists 
7.4.1 Drugs for urinary retention 
Parkinsonism Presence of Parkinsonism was 
assumed by dispensing of 
dopaminergic and 
antimuscarinic drugs used in 
those with Parkinson’s 
4.9.1 Dopaminergic drugs used in 
Parkinsonism 
4.9.2 Antimuscarinic drugs used in 
Parkinsonism 
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disease/Parkinsonism 
Uncomplicated peptic 
ulcer disease or erosive 
peptic oesophagitis 
An assumption was made 
that if a PPI was dispensed, it 
was being used for these 
conditions 
1.3.5 Proton Pump Inhibitors 
 
Moderate to severe 
COPD 
Presence of moderate-severe 
COPD was assumed by 
dispensing of short-acting 
beta2 agonist in combination 
with  long-acting muscarinic 
antagonist, long-acting beta2 
agonist plus inhaled 
corticosteroid 
3.1.1 Adrenoceptor agonists 
3.1.2 Antimuscarinic bronchodilators 
3.1.3 Theophylline 
3.1.4 Compound bronchodilator 
preparations 
3.2 Corticosteroids 
Asthma History of asthma was 
assumed by dispensing of 
beta2 agonist, inhaled 
corticosteroid, leukotriene 
receptor antagonist, 
theophylline 
3.1.1 Adrenoceptor agonists 
3.1.3 Theophylline 
3.2 Corticosteroids 
3.3.2 Leukotriene receptor 
antagonists 
Acute or chronic 
respiratory failure 
Respiratory failure was 
assumed by dispensing of 
oxygen 
3.6 Oxygen 
Severe hypertension Presence of severe 
hypertension was assumed by 
dispensing of ACE inhibitor 
(or angiotensin II receptor 
blocker) + calcium channel 
blocker + thiazide-like diuretic 
+ alpha blocker 
2.5.5.1 Angiotensin-converting 
enzyme inhibitors 
2.5.5.2 Angiotensin-II receptor 
antagonists 
2.5.4 Alpha-adrenoceptor blocking 
drugs 
2.2.1 Thiazides and related diuretics 
2.6.2 Calcium-channel blockers 
Severe heart failure Presence of severe heart 
failure was assumed by 
dispensing of ACE inhibitor 
(or angiotensin II receptor 
2.5.5.1 Angiotensin-converting 
enzyme inhibitors 
2.5.5.2 Angiotensin-II receptor 
antagonists 
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blocker) + beta-blocker + 
candesartan or 
spironolactone or eplerenone 
2.4 Beta-adrenoceptor blocking 
drugs 
2.2.4 Aldosterone antagonists 
 
Cardiovascular disease Cardiovascular disease was 
assumed by dispensing of any 
cardiovascular drug, e.g. 
diuretics; anti-arrhythmic 
drugs; beta-adrenoceptor 
blocking drugs; drugs for 
hypertension and heart 
failure; nitrates, calcium-
channel blockers, and other 
antianginal drugs; antiplatelet 
drugs; lipid-regulating drugs 
1.2 Positive inotropic drugs 
2.2 Diuretics 
2.3 Anti-arrhythmic drugs 
2.4 Beta-adrenoceptor blocking 
drugs 
2.5 Hypertension and heart failure 
2.6 Nitrates, calcium-channel 
blockers and other antianginal drugs 
2.7 Sympathomimetics 
2.8 Anticoagulants and protamine 
2.9 Antiplatelet drugs 
2.10 Stable angina, acute coronary 
syndromes, and fibrinolysis 
2.11 Antifibrinolytic drugs and 
haemostatics 
2.12 Lipid-regulating drugs 
 
Type 2 diabetes mellitus Presence of type 2 diabetes 
was assumed by dispensing of 
biguanides, sulphonylureas or 
other antidiabetic drugs 
indicated for type 2 diabetes 
6.1.2.1. Sulphonylureas 
6.1.2.2 Biguanides 
6.1.2.3 Other antidiabetic drugs 
Heart failure Presence of heart failure was 
assumed by dispensing of ACE 
inhibitor or angiotensin-II 
receptor antagonist in 
combination with a beta-
blocker licensed for use in 
heart failure (bisoprolol, 
carvedilol, nebivolol) 
2.5.5.1 Angiotensin-converting 
enzyme inhibitors 
2.5.5.2 Angiotensin-II receptor 
antagonists 
2.4 Beta-adrenoceptor blocking 
drugs 
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